Insider Selling: Tango Therapeutics, Inc. (NASDAQ:TNGX) CFO Sells 4,284 Shares of Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) CFO Daniella Beckman sold 4,284 shares of the company’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total value of $12,809.16. Following the completion of the sale, the chief financial officer now owns 154,232 shares of the company’s stock, valued at $461,153.68. This represents a 2.70 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Tango Therapeutics Stock Down 2.7 %

Shares of TNGX opened at $3.26 on Friday. Tango Therapeutics, Inc. has a 12-month low of $2.59 and a 12-month high of $12.89. The business has a 50-day simple moving average of $3.14 and a two-hundred day simple moving average of $6.12.

Hedge Funds Weigh In On Tango Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Dimensional Fund Advisors LP increased its stake in shares of Tango Therapeutics by 42.5% in the second quarter. Dimensional Fund Advisors LP now owns 335,913 shares of the company’s stock valued at $2,882,000 after buying an additional 100,257 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Tango Therapeutics by 8.1% in the second quarter. The Manufacturers Life Insurance Company now owns 29,511 shares of the company’s stock worth $253,000 after acquiring an additional 2,218 shares in the last quarter. SG Americas Securities LLC bought a new position in Tango Therapeutics in the third quarter worth approximately $151,000. China Universal Asset Management Co. Ltd. boosted its holdings in Tango Therapeutics by 64.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 20,607 shares of the company’s stock worth $159,000 after acquiring an additional 8,055 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of Tango Therapeutics in the third quarter valued at approximately $349,000. Institutional investors and hedge funds own 78.99% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on TNGX. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Tango Therapeutics in a research report on Thursday, December 5th. B. Riley cut their price objective on Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, November 11th. Guggenheim lowered their target price on Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $13.00 target price on shares of Tango Therapeutics in a research note on Friday, November 8th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $13.14.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.